SPRCSciSparc Ltd.

Nasdaq scisparc.com


$ 0.29 $ 0.00 (0.63 %)    

Wednesday, 18-Sep-2024 15:56:52 EDT
QQQ $ 472.49 $ -2.05 (-0.43 %)
DIA $ 416.26 $ -1.07 (-0.26 %)
SPY $ 562.20 $ -1.67 (-0.3 %)
TLT $ 99.62 $ -1.25 (-1.24 %)
GLD $ 235.53 $ -1.83 (-0.77 %)
$ 0.2895
$ 0.28
$ 0.29 x 400
-- x --
$ 0.27 - $ 0.30
$ 0.26 - $ 14.22
3,107,815
na
204,585
$ 1.85
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 clearmind-medicine-files-international-patent-for-ibogaine-combination-therapy

Clearmind Medicine filed an international patent for a treatment that aims to enhance addiction treatment safety and efficacy.

 reported-august-28-scisparc-files-for-sale-of-up-to-21m-ordinary-shares-under-20m-sepa-agreement-shares-priced-at-97-of-market-value-may-receive-up-to-882m

Reported August 28: SciSparc Files For Sale Of Up To 21M Ordinary Shares Under $20M SEPA Agreement; Shares Priced At 97% Of Mar...

 scisparc-grants-global-rights-for-pain-therapy-to-polyrizon-ltd-in-agreement-worth-up-to-6m-3m-in-polyrizon-securities-as-well-as-potential-milestone-fees-of-3m-in-cash

SciSparc would be entitled to receive consideration valued at $3 million in Polyrizon securities, as well as potential mileston...

 scisparc-submits-ind-application-to-the-fda-for-sci-110-phase-iib-clinical-trial-for-patients-with-tourette-syndrome

SciSparc to conduct the trial at the Yale Child Study Center at the Yale School of Medicine in the USA, Hannover Medical School...

 autism-cbd-trial-on-children-advances-as-israeli-company-enrolls-first-five-patients

SciSparc Ltd. (NASDAQ: SPRC) announced on Tuesday that the first five patients have been enrolled and dosed into its ongoing cl...

 israel-based-biotech-penny-stock-scisparc-outlicenses-its-cannabinoid-pain-therapy

SciSparc signs an exclusive license agreement with Polyrizon Ltd for its SCI-160 pain treatment program, with potential milesto...

 scisparc-finalizes-exclusive-global-out-licensing-agreement-with-polyrizon-for-sci-160-pain-therapy-program-valued-at-3m

SciSparc will receive consideration in shares, and in addition may receive cash payments and fees if certain development milest...

 scisparc-reports-courts-approval-of-automaxs-petition-to-convene-special-class-meetings-of-shareholders-to-approve-merger

SciSparc provides investors with an update regarding the status of the merger agreement with AutoMax, including the court's...

Core News & Articles

SciSparc has been collaborating with Clearmind Medicine to create effective treatments for obesity and metabolic syndrome by co...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION